Creative Biolabs Launched Bispecific T-cell Engager for Cancer Treatment and Immune Regulation

SHIRLEY, NY - Sep 4, 2018 - Sep 4, 2018, with more than ten years of experience in serving clinical researches and academic researches, Creative Biolabs developed bispecific t cell engager for cancer treatment and immune regulation researches.

Consisting of the variable regions from distinct antibodies, bispecific t cell engager (BiTE) is expressed by transfected mammalian cells which is formed by four tandem variable regions connected by flexible peptides. One of its paratopes targets to certain tumor-associated cell surface antigen, the other is binding to CD3 so as to recruit T cells. Without Fc region, its samller size (~55 kDa) gives BiTE a short serum half-life, it also ensures a closer proximity to the surface of both T cell and target cell. ompared wth other CD3-bispecific or IgG antibodies, BiTE has more than thousands of times of efficiency in lying cancer cells. What’s more, BiTE is able to direct multiple rounds of target cell lysis by T cells with a low effector cell even at a low concentration.

In Creative Biolabs, bispecific antibodies are also served as effective therapeutic agents in cancer immunotherapy, which also can gve this BiTE a credit. Equipped with advanced recombinant antibody platform and other multiple bioengineering platforms, Creative Biolabs is able to offer customers with time-saving and cost-effective services and products. Therefore, it is set up to provide BiTE targeting to any tumoe marker of interest with high affinity.

“A limitation of antibody-dependent immune cell-mediated cytotoxicity (ADCC) technology is that not all immune cells express the CD16 receptor. In particular, neither cytotoxic T cells nor helper T lymphocytes express CD16, and therefore interact with the corresponding antibodies and do not exert immunological killing effects. In order to overcome this limitation and enhance the ability of the adaptive immune system to kill tumor cells, a bispecific antibody design emerged.” Said Dr. Hoffman, one of a senor scientists in R&D of Creative Biolabs, “additinally, it is studied that BiTE is able to eiminate the tumor without affecting normal cells.”

About Creative Biolabs

Possessing unchallenged expertise and experience in recombinant antibody (rAb) discovery and manufacturing, Creative Biolabs is able to provide researchers with high-quality and professional BiTE to assist them success.